Furthermore, it was aimed to investigate whether TPα and/or TPβ expression might serve as surrogate biomarker(s) in PCa, correlating with Gleason grade, pathologic tumour staging (PTS) or with significant clinical outcomes, such as patient progression to BCR, potential for disease relapse and/or the development of the more severe aggressive forms of PCa. The gene discussed is PLAT; the disease is neoplasm.